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IFN-y occupies a central role as a potent modulator of both the affector and the
effector limbs of the immune response. While promising as a therapeutic agent for
immunodeficiency states, infectious and neoplastic diseases, and autoimmunity (1-3),
IFN-y has perhaps more often been evoked in the pathogenesis of such disorders
(4-9). In the latter regard particularly, recent evidence from transgenicmouse models
has clearly demonstrated that overexpression of IFN-y can result in autoimmune
destruction of tissues by inflammatory mechanisms (10). In the course of studying
the cell and molecular basis for IFN-y gene regulation (11), we observed an IFN
response consensus sequence in the most proximal 5' region of the human IFN-y
gene very near a T cell-specific, inducible DNAse I hypersensitive site 250 by from
that gene's cap site (12). Given the role of such response elements in upregulating
IFN responsive genes (13, 14), we queried whether the product ofthe human IFN-y
gene locus might somehow affect its own expression. In this article, definitive evi-
dence is presented using both total human PBMCs and specific subsets ofthosecells,
demonstrating a strong IFN-y autosuperinduction response to either IFN-y"priming
or costimulation.
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Materials and Methods
BriefDefinitive Report
For each experiment, human PBMC were isolated from 1 U of heparin-treated, random
donor buffy coats (GulfCoast Regional Blood Center, Houston, TX). All samples used were
negative by HIV and hepatitis serologies. PBMC were isolated by isoïymph gradient cen-
trifugation. Mixed leukocytes were washed in HBSS and suspended in RPMI 1640, 10%
FCS, penicillin/streptomycin at 5 x 106 cells/ml before stimulation. PBMC separated into
E+ and E- fractions (15) were first panned in plastic petri dishes at 37°C for 45 min to re-
move adherent cells. For reconstitution experiments, adherent monocytes from 3 x 107 cells
were added back to equal numbers of rosetted cells before stimulation. For co-stimulati
experiments, human rIFN-y (Genzyme Corp., Boston, MA) and PHA (final 1.0 g/ml) were
added simultaneously, the mixture was incubated at 37°C for 6 h, and nonadherent cells
were removed, washed three times in cold PBS, and used directly for total RNA isolation.
In preincubation (primed) experiments, cells as above were first incubated with rIFN (or
media alone) for 6 h at 37°C before addition of PHA. Preincubation of monocytes alone
with IFN-y had no effect on subsequent upregulation of IFN-y transcripts. IFN-y-primed
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cells used for analysis of IFN-y release were washed four times in coldPBS before lectin stim-
ulation as above . Culture supernatants were assayed for content ofIFN-y by RIA (Centocor,
Inc ., Baltimore, MD) . RNA was isolated by guanidine isothiocyanate disruption of cells and
cesium gradient ultracentrifugation . RNA was quantified by OD256o ; 15 g per lane was used .
Ethidium staining and photographic verification ofRNA load and integrity were performed
in every case . Northern analyses oftranscripts were determined by hybridization withcDNA
probes ofhuman IFN-y and 0-actin 32P labeled to 0.5-1.0 x 109 cpm/g . Autoradiograms were
densitometrically analyzed and computer integrated for direct comparison (Pharmacia/LKB
Biotechnology, Inc ., Piscataway, NJ) . Cytometric analysis of total PBMC and rosette E' and
E- cells used mAbs, Leu 3a, 4, 9, 11, 12, M3, and FITC-labeled goat anti-mouse (Becton
Dickinson & Co ., Mountain View, CA) .
Results and Discussion
To address our hypothesis that human IFN-y might affect its own gene expres-
sion, total human PBMC were differentially lectin activated either alone, in the pres-
ence of rIFN-y, or after 6 h of priming with rIFN-y . IFN-ymRNA transcripts were
then measured by Northern analysis using /3-actin as internal control . As is shown
in Fig. 1, PBMC either co-stimulated or primed with IFN-y upregulated that gene's
expression at the steady-state mRNA level . Cells primed with IFN-y demonstrated
a significantly stronger response than those simply co-stimulated . Even subthreshold
concentrations ofPHA became stimulatory for IFN-y gene induction when as little
as 10 U/ml ofrIFN-y was present . Upregulation was even stronger, however, with
higher levels ofPHA (1.0 g/ml) . Among different individuals, range of upregulation
varied between 3- and 50-fold . IFN-y concentrations>500 U/ml rarely had any fur-
ther effect on this upregulatory response .
Next, PBMC mock primed or primed with IFN-y as above were stimulated with
threshold levels of PHA and assessed at various times for IFN-'y transcripts . As is
quantified densitometrically in Fig . 2, onset ofIFN-y gene induction occurred 4-fold
faster and expression was nearly 30-fold higher in IFN-y-primed PBMCs . High
FIGURE 1 .
￿
Effect of purified IFN-yon itsowngene expression in PHA-activated PBMC . Total
human PBMCs were either co-stimulated (A andB) or primed for 6 h (C and D) with rIFN-y
at concentrations shown, then analyzed for induction of IFN-'r-specificmRNA 6h after stimula-
tion with concentrations ofPHA as shown . Each lane contains 15 g of total RNAfrom 5 x 10'
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kinetics oftheIFN-y autosuperinduc-
tion response . TotalPBMC wereprimed with rIFN-y (500
Ulml)for6hthenPHAstimulated (1 .0 glml)anddisrupted
at the times indicated before RNA isolation and analysis
ofIFN-y-specific mRNA . Autoradiograms in top panelrep-
resent IFN-y specific signal from (A)non-IFN-primed cells
and (B) IFN-primed cells. Bottom panel showsdensitometric
quantification ofthese kinetics determined at each time point
relative to actin-specific signal (calculated by : ODIFNI
ODaetin).
level expression was maintained for several days before tapering back to near control
levels . Furthermore, in N30% of PBMC samples studied to date, IFN-y priming
resulted in some induction ofIFN-y transcripts even in the absence of lectin stimu-
ig . 2) .
De novo synthesis of biologically active IFN-y after mock ofIFN-y priming and
lectin activation ofPBMC was also measured usingconventional RIAanalysis (data
not shown) . Even as early as 6 h after stimulation, washed cells primed with IFN-y
released nearly seven times more biologically active IFN-y into the mediathan did
unprimed cells . This suggested that IFN-yprimingnotonly upregulated IFN-y gene
expression but also IFN-y protein synthesis and release .
The question of subset identification ofPBMC involved in the IFN-y autosuperin-
duction response was next addressed . As is shown in Fig . 3 A, a typically strong
and dose-related response wasobserved in totalPBMCs . Surprisingly, however, rosetted
Tcells from the same patientwhether monocyte depleted (Fig. 3B) or repleted (Fig .
3 C) failed to demonstrate the upregulatory response, despite their normal activa-
FIGURE 3. Identification of
lymphocyte subset involvement
in the IFN-y autosuperinduc-
tion response. TotalPBMC (A);
E*, monocyte depleted (B); E*,
monocyte reconstituted(C); and
E- cells (D) were primed with
rIFN-y as indicated andIFN-y
mRNA was assayed 6 h after
stimulation with 1.0 gfml of
PHA . Controlhybridization to1024
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tional dependence on monocytes for IFN-y induction. As is shown quite clearly in
Fig. 3 D, however, the E- mononuclear cells are quite readily superinduced by
IFN-y priming. Flow cytometric analysis of the E- cells revealed absence of T3+
lymphocytes, N60-70% Leu 12+ (B cells), 16-25% Leu 11+ NK cells, and variable
(0-8%) percentages of Leu M3+ (monocytes) cells depending on prior panning.
These data are consistent with the notion that accessory cells (i.e., B cells and/or
monocytes) in the E- fraction might themselves be the targets ofIFN-y priming,
and that these cells, or their soluble products, might indirectly be responsible for
the upregulation ofthe NK-like cellsin that fraction. However, neither supernatants
from the primed E- fraction nor IFN-y-primed monocytes are capable of recon-
stituting this response when added to E+ fractions. Further, total cells from the E"
fraction, when added back to the E' fraction, did not reconstitute a response addi-
tively any greater than the sum ofthe two fractions alone (data not shown). Since
only T cells and LGLs express IFN-y (16-18), our data suggest that the producer
cells largely involved in the IFN-y autosuperinduction response are primarily non-
rosettable mononuclear cells, presumably ofthe NK type. They also imply that E+
lymphocytes do not participate in this response, even in the presence ofvarious ac-
cessory cells and/or their products. Further, preliminary data from analyses ofIL-2
mRNA transcripts argue against a role for IL-2 in this response.
TNFot (19), IL-1(20), platelet-derivedgrowth factor (PDGF) (21), andbothTGFa
and -a (22-23) have all been recently implicated in self-amplification loops, sup-
porting a general model involvingwidespread autocrine/paracrine regulationwithin
the cytokine system. Our observations ofhuman IFN-yautosuperinduction extend
theseearlierfindings and maybe particularly relevant to thepathogenesis and treat-
ment ofimmunologic disease. Our findings that the response particularly involves
NK-like cells may lend credence to trials of its use in combination with IL-2 in
lymphokine-activated killer cell/tumor-infiltrating lymphocyte (LAK/TIL) therapy
protocols. Important to autoimmune disease pathogenesis, however, is the fact that
autocrineor paracrine upregulation ofapotent inflammatory mediator such asIFN-y
wouldbepredictedtohave direinflammatory consequences unless opposedbypowerful
and critically regulated suppressive mechanisms. Suppression ofhuman IFN-ybio-
logical activity (24) and gene expression (11) has very recently been attributed to
a similarly autoinducible lymphokine, TGF/3. It has been shown that TGF-/3 is an
immunosuppressive cytokine produced by rat macrophages (25). We have recently
identified TGF0 in a murine MLR supernatant and shown it to be a physio-
logic downregulator ofmurine IFN-y gene expression (26). Perhaps it is no coinci-
dence that IFN-y, an upregulator ofimmune responsiveness and inflammation, is
naturally opposed by TGF/3, a downregulator of inflammation and a promoter of
wound healing (27). Furtherinsightsintothe cell and molecular genetic mechanisms
regulating these and other members ofthe cytokine system should provide a foun-
dation upon which to design more effective immunotherapeutic regiments, based
on a more realistic understanding of the pathogenesis of immune dysfunction.
Summary
The product ofthe human IFN-y gene was found to be a powerful upregulatory
stimulus for its own gene expression in lectin-activated human PBMC. The IFN-y
autosuperinduction response was further enhanced by "priming"PBMC with IFN-y.HARDY AND SAWADA
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Primed cells maximallyupregulated theirlevels of IFN-y specific mRNA 4-fold faster
and more than 20-fold higher than mock-stimulated cells. High mRNA levels per-
sisted for several days after stimulation, and enhanced secretion of biologically ac-
tive IFN-y paralleled the observed upregulation of gene expression . Producer cells
demonstrating this response were found to be primarily localized to the rosette E-
(Leu 11') fraction of PBMC and appear to be of the LGL/NK variety. Whether
the autosuperinduction phenomenon occurs throughdirect or indirect effects ofIFN-y
on producer cells is still unclear. These results may be important both to an under-
standing ofthe pathogenesis of immune dysfunction and to the design ofmore effec-
tive immunotherapy.
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